澳大利亚和新西兰（ANZ）地区慢性淋巴细胞白血病（CLL）是最常见的血液恶性肿瘤。在过去十年中，诊断和治疗算法发生了相当大的改变。下一代测序技术和流式细胞术测量残留疾病的可行性，可以进行先进的预后评估和治疗反应评估。包括布鲁顿酪氨酸激酶（BTKi）抑制剂和B细胞淋巴瘤2（BCL2）抑制剂在内的新型疗法，已经改变了初治和复发/难治性疾病的治疗格局，尤其适用于具有高风险基因异常的患者。针对适当的支持性管理的建议仍在不断演变，对于CLL患者在全球SARS-CoV-2大流行情况下，需考虑特殊因素。澳大利亚-亚太地区的独特资金和治疗环境凸显了对CLL调查和治疗的特定本地指导的需求。这项共识实践声明由广泛代表ANZ CLL专家的团体开发，并得到了最高血液学机构的认可，旨在提供这些标准化指导。“© 2023 作者。由澳大利亚John Wiley＆Sons有限公司出版的《内科学杂志》代表澳大利亚皇家医师学院发表。”

Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in Australia and New Zealand (ANZ). Considerable changes to diagnostic and management algorithms have occurred within the last decade. The availability of next-generation sequencing and measurable residual disease assessment by flow cytometry allow for advanced prognostication and response assessments. Novel therapies, including inhibitors of Bruton's tyrosine kinase (BTKi) and B-cell lymphoma 2 (BCL2) inhibitors, have transformed the treatment landscape for both treatment-naïve and relapsed/refractory disease, particularly for patients with high-risk genetic aberrations. Recommendations regarding appropriate supportive management continue to evolve, and special considerations are required for patients with CLL with respect to the global SARS-CoV-2 pandemic. The unique funding and treatment environments in Australasia highlight the need for specific local guidance with respect to the investigation and management of CLL. This consensus practice statement was developed by a broadly representative group of ANZ experts in CLL with endorsement by peak haematology bodies, with a view to providing this standardised guidance.© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.